Research Overview
It is a modified GLP-1 analog designed to resist enzymatic degradation by dipeptidyl peptidase-4 (DPP-4), resulting in prolonged receptor interaction in experimental models [1]. In preclinical and molecular studies, It is used to investigate GLP-1 receptor signaling, cyclic AMP (cAMP) pathways, and downstream effects on insulin and glucagon regulation at the cellular level [2].
Applications in Scientific Research
In laboratory and animal research settings, it is commonly studied in metabolic, endocrine, and neurobiological research models. Published literature explores its role in pancreatic beta-cell signaling, appetite-regulating neural pathways, and energy homeostasis under controlled experimental conditions [3]. Additional research has examined GLP-1 receptor agonists like it in cardiovascular and inflammatory signaling models, as well as central nervous system receptor expression studies [4][5]. These investigations have positioned it as a key reference compound for researchers examining incretin biology, peptide modification strategies, and receptor-driven metabolic signaling. This material is intended solely for research and analytical purposes and is not approved for human or veterinary use.
Referenced Citations
- Knudsen L.B. et al. “Glucagon-like peptide-1 derivatives as long-acting receptor agonists.” Journal of Medicinal Chemistry.
https://pubmed.ncbi.nlm.nih.gov/21568269/
- Drucker D.J. “The biology of incretin hormones.” Cell Metabolism.
https://pubmed.ncbi.nlm.nih.gov/18691966/
- Campbell J.E., Drucker D.J. “Pharmacology, physiology, and mechanisms of incretin hormone action.” Cell Metabolism.
https://pubmed.ncbi.nlm.nih.gov/24836535/
- Marso S.P. et al. “GLP-1 receptor agonists and cardiovascular mechanisms.” New England Journal of Medicine.
https://pubmed.ncbi.nlm.nih.gov/27633186/
- Secher A. et al. “Central nervous system sites of GLP-1 receptor agonist action.” Diabetes.
https://pubmed.ncbi.nlm.nih.gov/26678000/